Anemia in End-Stage Renal Disease
Understanding Anemia in End-Stage Renal Disease (ESRD) is crucial for healthcare professionals. This resource provides information on Anemia of ESRD, also known as Renal Anemia, including clinical documentation tips and medical coding guidance for accurate diagnosis and treatment. Learn about the connection between anemia and ESRD, relevant lab values, and best practices for managing this condition. Improve your clinical documentation and medical coding accuracy with this comprehensive guide to Anemia in End-Stage Renal Disease.
Decreased red blood cell count due to impaired erythropoietin production by damaged kidneys.
Fatigue, weakness, shortness of breath, pale skin, dizziness, rapid heart rate.
Patients with chronic kidney disease stage 5 (CKD-5) or end-stage renal disease (ESRD) requiring dialysis.
ICD-10 Code Families
Complete code families applicable to D63.1
When to use each related code
| Description | When to use |
|---|---|
| Low red blood cell count due to kidney failure. | Document for anemia specifically caused by chronic kidney disease stage 5. |
| Low red blood cell count from other causes. | Use when anemia is not directly due to kidney dysfunction. Specify the cause. |
| Kidney failure requiring dialysis or transplant. | Code for established end-stage renal disease managed with dialysis or transplant. |
Best-practice checklist
- ✓Document anemia severity (hemoglobin/hematocrit).
- ✓Specify ESRD diagnosis and stage.
- ✓Note iron studies (ferritin, transferrin saturation).
- ✓Document EPO deficiency, if present.
- ✓Record anemia treatment plan (e.g., ESA, iron).
Common pitfalls to avoid
Coding requires specifying the type of anemia (e.g., deficiency, aplastic) present in ESRD for accurate reimbursement.
Insufficient documentation of ESRD diagnosis and its link to anemia can lead to coding errors and claim denials.
Other conditions mimicking or contributing to anemia in ESRD require careful differentiation for accurate code assignment.
Best-practice tips
- 01Monitor hemoglobin regularly (ICD-10 N18.3, D63.8).
- 02Consider ESA therapy (EPO, darbepoetin) per guidelines (ICD-10 Z92.2).
- 03Manage iron levels via IV iron or oral supplements (ICD-10 E70.9).
- 04Optimize dialysis adequacy and address underlying causes (CDI focus).
- 05Document anemia management in detail for compliance (HCC coding).
Step-by-step checklist
- 1
Verify Hb level <10 g/dL (ICD-10 D63.1)
- 2
Confirm eGFR <15 mL/min/1.73m2 or dialysis (N18.5, Z99.2)
- 3
Assess iron studies (serum ferritin, transferrin saturation)
- 4
Evaluate for other anemia causes (B12, folate deficiency)
Ready-to-paste narrative
Patient presents with signs and symptoms consistent with anemia in end-stage renal disease (ESRD). The patient's chronic kidney disease stage 5 is documented, and laboratory results reveal a decreased hemoglobin level, hematocrit, and red blood cell count. Symptoms reported include fatigue, weakness, shortness of breath on exertion, and pallor. The patient's decreased erythropoietin production secondary to renal failure is the likely etiology of this anemia of ESRD, also known as renal anemia. Differential diagnoses considered included iron deficiency anemia, anemia of chronic inflammation, and thalassemia. Iron studies, including ferritin and transferrin saturation, were ordered to evaluate for iron deficiency. A complete blood count with differential and reticulocyte count was performed to assess red blood cell indices and bone marrow response. Treatment options for this chronic kidney disease-related anemia include erythropoiesis-stimulating agents (ESAs) and iron supplementation if indicated. Risks and benefits of ESA therapy were discussed with the patient, including monitoring for adverse effects such as hypertension and thromboembolic events. Patient education regarding dietary modifications and management of anemia symptoms was provided. Follow-up laboratory testing is scheduled to monitor hemoglobin levels and response to therapy. ICD-10-CM code N18.3 and appropriate CPT codes for evaluation and management, as well as laboratory services, will be documented for billing and coding purposes.
Common questions and answers
What are the best evidence-based strategies for managing anemia of ESRD in patients with chronic kidney disease stage 5?+
Managing anemia of ESRD (also known as renal anemia or anemia in end-stage renal disease) in CKD stage 5 patients requires a multifaceted approach. Current guidelines from KDIGO recommend targeting a hemoglobin level of 10-11.5 g/dL, avoiding higher targets. Erythropoiesis-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa, are commonly used but should be titrated carefully to minimize risks. Iron therapy is crucial, as iron deficiency is common in ESRD. This may involve intravenous iron administration if oral iron is insufficient. Adequate dialysis is essential for clearing uremic toxins that contribute to anemia. Explore how optimizing dialysis frequency and modality can improve anemia management outcomes. Consider implementing regular monitoring of hemoglobin, iron status (ferritin, transferrin saturation), and ESA responsiveness to individualize therapy and minimize adverse events. Learn more about the potential benefits and risks of newer agents like hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in this patient population.
How do I differentiate between iron deficiency anemia and anemia of chronic disease in a patient with end-stage renal disease?+
Differentiating iron deficiency anemia (IDA) from anemia of chronic disease (ACD), also called anemia of inflammation, in ESRD patients can be challenging since both are common. While both conditions can present with low hemoglobin, key distinguishing factors include iron studies. In IDA, ferritin is low and transferrin saturation (TSAT) is also low. In ACD, ferritin may be normal or even high due to inflammation, while TSAT remains low. However, in patients with ESRD, ferritin can be elevated due to inflammation even in the presence of true iron deficiency. Therefore, measuring hepcidin levels can be helpful, as hepcidin is typically elevated in ACD but not in IDA. Bone marrow iron stores assessment, though rarely performed, can provide a definitive diagnosis. Consider implementing a comprehensive evaluation of iron status, including ferritin, TSAT, and hepcidin, to guide appropriate iron supplementation in ESRD patients with anemia. Learn more about interpreting iron studies in the context of chronic kidney disease.
What are the common complications associated with untreated or undertreated anemia in end-stage renal disease patients?+
Untreated or undertreated anemia in end-stage renal disease (ESRD) can lead to a cascade of complications. Cardiovascular issues are a significant concern, as anemia increases cardiac workload and can worsen pre-existing heart conditions like left ventricular hypertrophy. Patients may experience decreased exercise tolerance, fatigue, and reduced quality of life. Cognitive impairment and depression are also observed in patients with significant anemia. Undermanaged anemia can contribute to increased hospitalization rates and mortality risk in ESRD. Explore how proactively addressing anemia can improve overall patient outcomes. Consider implementing regular assessments of hemoglobin levels and symptoms to guide timely intervention and optimize treatment strategies for anemia in ESRD. Learn more about the impact of anemia on cardiovascular health in patients with chronic kidney disease.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.